0001062822-26-000065
SEC filingLexicon Pharmaceuticals converted all Series B Preferred Stock into 20.4 million common shares, doubled authorized common stock to 900 million, approved expanded equity incentive plans, and elected directors at its April 30, 2026 annual meeting.
The conversion of all outstanding Series B Convertible Preferred Stock into over 20 million common shares significantly increases the public float, potentially enhancing liquidity but introducing dilution for existing common shareholders. This automatic conversion, triggered by predefined conditions without holder investment decisions, relied on the Section 3(a)(9) exemption, confirming no new fundraising but completion of a prior private placement at $65 per Preferred share. Concurrently, the Seventh Amended Certificate doubles authorized common stock to 900 million, providing substantial flexibility for future equity issuances, including under the newly approved incentive plans. The 2026 Equity Incentive Plan boosts the share reserve by 15 million to 90 million total, while the Directors’ Plan adds 2 million to reach 6 million, both extended to 2036—critical for attracting and retaining talent amid biotech sector competition. Strong shareholder support across all proposals, including director elections (over 98% For) and auditor ratification (over 99%), signals alignment and governance stability. These changes strengthen Lexicon's capital structure and compensation framework, positioning it for growth initiatives.